The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
Publication
, Journal Article
Califf, RM; Kramer, JM
Published in: Pharmacoepidemiol Drug Saf
August 2008
Duke Scholars
Published In
Pharmacoepidemiol Drug Saf
DOI
EISSN
1099-1557
Publication Date
August 2008
Volume
17
Issue
8
Start / End Page
782 / 786
Location
England
Related Subject Headings
- United States Food and Drug Administration
- United States
- Thiazolidinediones
- Rosiglitazone
- Public Policy
- Product Surveillance, Postmarketing
- Pharmacology & Pharmacy
- National Institutes of Health (U.S.)
- Hypoglycemic Agents
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Califf, R. M., & Kramer, J. M. (2008). The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. Pharmacoepidemiol Drug Saf, 17(8), 782–786. https://doi.org/10.1002/pds.1617
Califf, Robert M., and Judith M. Kramer. “The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.” Pharmacoepidemiol Drug Saf 17, no. 8 (August 2008): 782–86. https://doi.org/10.1002/pds.1617.
Califf RM, Kramer JM. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):782–6.
Califf, Robert M., and Judith M. Kramer. “The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.” Pharmacoepidemiol Drug Saf, vol. 17, no. 8, Aug. 2008, pp. 782–86. Pubmed, doi:10.1002/pds.1617.
Califf RM, Kramer JM. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):782–786.
Published In
Pharmacoepidemiol Drug Saf
DOI
EISSN
1099-1557
Publication Date
August 2008
Volume
17
Issue
8
Start / End Page
782 / 786
Location
England
Related Subject Headings
- United States Food and Drug Administration
- United States
- Thiazolidinediones
- Rosiglitazone
- Public Policy
- Product Surveillance, Postmarketing
- Pharmacology & Pharmacy
- National Institutes of Health (U.S.)
- Hypoglycemic Agents
- Humans